Despite the considerable buzz surrounding GLP-1 weight-loss drugs such as Wegovy and Zepbound, they fail to benefit every patient. Approximately 17% of users are classified as non-responders, prompting a search for alternatives. A novel medication is poised to enter the market; although the Food and Drug Administration has not granted approval, individuals are already pursuing it despite the lack of regulatory clearance for now.
The New Player in Weight Loss
Retatrutide is a medication that acts on three different receptors in the body, making it a triple-agonist, whereas Wegovy only acts on one receptor and Zepbound works on two.
Retatrutide is already being hailed as a breakthrough in an area of health that has already welcomed plenty of impressive medications in the past few years. In fact, clinical trial results show that it is so effective for weight loss that some participants have dropped out of the trials because they felt that they lost too much weight.
Despite its promise, retatrutide is still in the experimental stage and has not been approved by the FDA, with Eli Lilly, its manufacturer, yet to submit trial results for approval, and some versions are being sold online at low prices.
According to Mir Ali, retatrutide is not available for general use yet, and the only way to access it is by participating in a clinical trial, with no set timeline for its release to the market.
What Is It and How Does It Work?
Retatrutide shares some similarities with GLP-1 medications, such as being used for weight loss and administered via weekly injection, and it works by reducing appetite and slowing digestion, similar to Wegovy, Ozempic, and Zepbound.
But retatrutide has more going on than that. This medication acts on three hormone receptors in the body—glucagon-like peptide-1, gastric inhibitory polypeptide, and glucagon. This is the first one in the pipeline to work on three different receptors, according to Dr. Ali. The theory is that the more receptors it affects, the more effective the drug will be.
The medication is currently in phase-three clinical trials, and it has had some impressive results that suggest it could be the most effective drug for weight loss yet. The latest clinical trial results show that participants lost an average of 28.7 percent of their body weight on the highest dose of retatrutide over 68 weeks. By comparison, tirzepatide users lost an average of 15 percent to 22.5 percent over 72 weeks during clinical trials, and semaglutide users lost 10 percent to 15 percent of their body weight over 68 weeks during clinical trials.
While the data is compelling, the history of obesity drugs offers a cautionary note. When tirzepatide first showed similar dramatic results in early trials, it took years for the FDA to review the data and approve the medication. The path from promising trial results to an approved prescription is rarely a straight line. Regulators must weigh long-term safety data against short-term efficacy, often requiring years of additional research to ensure that a drug’s benefits outweigh its risks.
How Are People Finding It?
The FDA has issued a press release emphasizing that it is illegal to sell retatrutide and another experimental weight loss medication, cagrilintide, and that these medications cannot be used in compounding under federal law.
Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.
The FDA also noted that its officials have issued warning letters to companies that are distributing these medications.
Current Availability and Legal Status
Pharmacies are selling the drug online, though finding it requires effort. The FDA states that retatrutide cannot be compounded under federal law. It is not a component of an approved drug and has not been found safe or effective.
Why Doctors Advise Caution
This is hardly shocking, but doctors want people to take a pass on using retatrutide before it is FDA-approved. People should wait to take medications until they are approved by the FDA to maximize safety, Richard Siegel says. All scientific data in animals initially and then humans are carefully reviewed by the FDA for any signals that a medication may be harmful.
Alternatives for Non-Responders
Dr. Siegel points out that there are a lot of options to lose weight right now. And, if a person has not had success on one, he recommends talking to a health care provider about trying a different medication or strategy. If someone has not had luck while working with a primary care physician, Dr. Ali suggests seeing an obesity medicine specialist who will be more knowledgeable about treatment options.
